Factors affecting the pharmacokinetic characteristics of rapacuronium

Anesthesiology

Volumn 90, Issue 4, 1999, Pages 993-1000

  Fisher, Dennis M ^a   Kahwaji, Raymond ^b   Bevan, David ^b   Bikhazi, George ^b   Fragen, Robert J ^b   Angst, Martin S ^b   Ornstein, Eugene ^b   Matteo, Richard S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Modeling; Muscle relaxants; ORG9487; Population analysis

Indexed keywords

3 DESACETYLRAPACURONIUM; DRUG METABOLITE; FENTANYL; HEMOGLOBIN; NITROUS OXIDE; PROPOFOL; RAPACURONIUM BROMIDE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG ELIMINATION; DRUG POTENCY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; NEUROMUSCULAR BLOCKING; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUROMUSCULAR NONDEPOLARIZING AGENTS; VECURONIUM BROMIDE;

EID: 0032960301     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199904000-00011     Document Type: Article

References (12)

1. Kahwaji R, Bevan DR, Bikhazi G, Shanks CA, Fragen RJ, Dyck JB, Angst MS, Matteo R: Dose-ranging study in younger adult and elderly patients of ORG 9487, a new, rapid-onset, short-duration muscle relaxant. Anesth Analg 1997; 84:1011-8
2. Szenohradszky J, Caldwell JE, Wright PMC, Brown R, Lau M, Luks AM, Fisher DM: Influence of renal failure on the pharmacokinetics and neuromuscular effects of a single dose of rapacuronium bromide. ANESTHESIOLOGY 1999; 90:24-35
3. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41
4. Rupp SM, Castagnoli KP, Fisher DM, Miller RD: Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ANESTHESIOLOGY 1987; 67:45-9
5. Lien CA, Matteo RS, Ornstein E, Schwartz AE, Diaz J: Distribution, elimination, and action of vecuronium in the elderly. Anesth Analg 1991; 73:39-42
6. Matteo RS, Ornstein E, Schwartz AE, Ostapkovich N, Stone JG: Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. Anesth Analg 1993; 77:1193-7
7. Beemer GH, Bjorksten AR, Crankshaw DP: Effect of body build on the clearance of atracurium: Implication for drug dosing. Anesth Analg 1993; 76:1296-303
8. Wright PMC, Brown R, Lau M, Fisher DM: A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide. ANESTHESIOLOGY 1999; 90:16-23
9. Bowman WC, Rodger IW, Houston J, Marshall RJ, McIndewar I: Structure:action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. ANESTHESIOLOGY 1988; 69:57-62
10. Schiere S, Proost JH, Wierda JMKH: Pharmacokinetics and pharmacokinetic/pharmacodynamic (PK/PD) relationship of ORG 9488, the 3-desacetyl metabolite of ORG 9487 (abstract). ANESTHESIOLOGY 1997; 87:A377
11. van den Broek L, Wierda JM, Smeulers NJ, Proost JH: Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. Br J Anaesth 1994; 73:331-5
12. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle A, Cox K: The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ANESTHESIOLOGY 1997; 87:36-50